[ad_1]
Strasbourg, France, March 27, 2024, 5:45 pm CET – Transgene (Euronext Paris: TNG), a biotechnology company designing and developing viral immunotherapies for the treatment of cancer, is pleased to announce the appointment of Lucie Larguier as Chief Financial Officer (CFO), effective immediately. Lucie Larguier previously served as Transgene’s Vice President of Corporate Communications and Investor Relations. In her new role as Chief Financial Officer, Lucie Larguier will be responsible for all aspects of the company’s financial strategy, management and operations to ensure the efficient delivery of Transgene’s innovative immunotherapy product lines. Lucie succeeds Arnaud Dubarry, who has resigned to pursue other opportunities.
Already a member of the Executive Management Committee, Lucie Larguier has a comprehensive, cross-functional understanding of the company’s operations and financials, as well as an in-depth understanding of Transgene’s investor base. Since 2016, Lucie has served as Director of Corporate Communications and Investor Relations, reporting directly to the Chief Executive Officer. Lucie made significant contributions to the smooth execution of four successful securities transactions and enhanced Transgene’s external visibility. Prior to joining Transgene, Lucie worked in the consulting field for over 10 years, advising companies on corporate and financial information and contributing to the success of many securities transactions. She graduated from Sciences Po in Paris with a master’s degree in communication and a minor in finance.
In addition to this new appointment, Transgene has promoted Christelle Schwoerer to Chief Human Resources Officer, effective April 1, 2024, and she has joined the Executive Committee. Christelle Schwoerer joined Transgene’s Human Resources department in 2013 and her knowledge of the organization, culture and people is a real asset in her new, expanded role. Christelle Schwoerer received the Master’s Degree in Human Resources from CNAM Grand-Est1 in 2020 and the Master’s Degree in Management and Human Resources from Strasbourg School of Management in 2021, respectively.
Alessandro Riva, Transgene Chairman and CEO, MD, commented: “I have worked extensively with Lucie since taking on the role of CEO, and I believe her knowledge and experience make her a perfect fit to serve as Transgene’s Chief Financial Officer. She is a strong believer in the culture we are building and has contributed to the company’s success to date. has made a significant contribution and is well positioned to support our ambitious plans to accelerate the development of our highly promising cancer immunotherapies.”
Chief Financial Officer Lucie Larguier said: “I am extremely excited to serve as Transgene’s Chief Financial Officer. I believe the company is at a critical juncture with ongoing clinical development programs that, if positive, can drive significant value to the company and its shareholders over the next one to two years. I look forward to working with Senior The management team works closely together to help ensure the success of our exciting pipeline of cancer immunotherapy assets.”
***
About genes
Transgene (Euronext: TNG) is a biotechnology company focused on the design and development of targeted immunotherapies for the treatment of cancer. Transgene’s program uses viral vector technology and is designed to kill cancer cells either indirectly or directly.
The company’s clinical-stage programs include a portfolio of therapeutic vaccines and oncolytic viruses:
TG4050, the first based on Maiwak® platform, TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO® viral backbone.
genetically modified Maiwak® platform, therapeutic vaccination enters the field of precision medicine with novel immunotherapies that are completely tailored to each individual.this Maiwak® approach allows the generation of virus-based immunotherapies encoding patient-specific mutations identified and selected by artificial intelligence capabilities provided by its partner NEC.
Leveraging its proprietary platform, Invir.IO®, Transgene is leveraging its viral vector engineering expertise to engineer a new generation of multifunctional oncolytic viruses.
For more information about Transgene, please visit: www.transgene.fr
Follow us on social media: X (formerly Twitter): @genemodifiedSA – LinkedIn: @genetically modified
contact method
Disclaimer
This press release contains forward-looking statements that are subject to a number of risks and uncertainties that could cause actual results to differ materially from expectations. The occurrence of any of these risks could have material negative consequences on the Company’s activities, prospects, financial condition, performance, regulatory and development stage agreements and developments. The Company’s ability to commercialize its products depends on, but is not limited to, the following factors: positive preclinical data that may not predict human clinical outcomes, success of clinical studies, the ability to obtain financing and/or product manufacturing partnerships, development and commercialization, and government Marketing approval from regulatory authorities. For a discussion of the risks and uncertainties that could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in forward-looking statements, please see General’s Risk Factors (“Facteurs de Risque”) section. Registration documents are available on the AMF website (http://www.amf-france.org) or the Transgene website (www.transgene.fr). Forward-looking statements speak only as of the date they are made, and Transgene assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.
attachment
[ad_2]
Source link